HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Toxicity, second cancers cause researchers to question radiation’s role in Hodgkin lymphoma
-
- Symposium findings provide ‘wake-up call’ about postoperative complications, registry discrepancies Nicholas J. Petrelli, MD, FACS
- Alcohol and cancer risk: What is the connection?
- ASCO names new CEO
- Association of Community Cancer Centers names new president
- Bladder cancer institute awards $500,000 worth of research grants
- Dana-Farber Cancer Institute names new president, CEO
- GW Cancer Center appoints associate director for patient-centered initiatives
- Lewis C. Cantley, PhD, receives Wolf Prize in Medicine
-
- Pediatric Blood and Marrow Transplant Consortium presents lifetime achievement award
- Society of Gynecologic Oncology appoints new CEO
- The University of Texas MD Anderson Cancer Center honors faculty
- Pancreatic Cancer Drugs in the Pipeline
- Propensity matching and the GIGO principle Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Kovaltry for hemophilia A
- FDA approves Xalkori to treat ROS1-positive NSCLC
- FDA grants orphan drug designation to BPX-501 for GVHD, immunodeficiency after stem cell transplants
-
- FDA grants orphan drug designation to WT1 cancer vaccine for malignant pleural mesothelioma
- FDA grants priority review to MPDL3280A for treatment of advanced, metastatic urothelial carcinoma
- FDA reports increase of adverse events with Zydelig, six trials stopped
- A 57-year-old woman with an anterior mediastinal mass of unusual histology Munir Ghesani, MD, FACNM; Ajit Karakbelkar, MD
- ASCO: Expanded genetic testing should be standard for metastatic colorectal cancer
- Circulating histones may predict thrombocytopenia severity in ICU patients
- Clonal abnormalities may serve as diagnostic tool for blood cancers
- Combination therapy may extend OS in metastatic pancreatic cancer
-
- Common genetic variants linked to high VTE incidence in black patients
- CYP3A7 allele predicts poor outcomes for lung and breast cancer, leukemia
- ED interventions reduce time to treatment of febrile neutropenia
- Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs
- Financial burden linked to depression in cancer survivors
- Gemtuzumab ozogamicin response linked to CD33 expression level in pediatric AML
- Hospitalization for heart failure may predict VTE risk
- HSCT may improve DFS, OS in older patients with AML
-
- Imetelstat demonstrates safety, efficacy for essential thrombocythemia
- Intensive, multi-agent regimen may prolong EFS in metastatic rhabdomyosarcoma
- Most patients with advanced cancer want genetic testing results
- Neoadjuvant chemotherapy demonstrates favorable outcomes in pediatric germ cell tumors
- Poor, minority AYAs less likely to survive Hodgkin’s lymphoma
- Poor OS observed in men with brain metastases from germ cell tumors
- PSA testing rates differ among urologists, PCPs
- RAS/MAPK hyperactivation may predict worse outcomes in undifferentiated pleomorphic sarcomas
-
- Ropeginterferon alfa 2b shows promise for polycythemia vera
- Routine CT scans after SBRT effectively detect NSCLC progression
- Shorter bleomycin regimen demonstrates acceptable toxicity profile in older patients with Hodgkin lymphoma
- Trial availability, patient eligibility barriers to enrollment onto genomically matched trials
- Tumor-treating fields prolong PFS, OS in glioblastoma
- USPSTF: Insufficient evidence exists for anemia testing, iron supplementation in pregnant women
- Benefits, harms of routine skin cancer screening uncertain
- Bone density scans underutilized after prophylactic oophorectomy
-
- Brain may become ‘just another organ’ in treatment of metastatic melanoma
- Clinical trials ‘remain the priority’ for patients with uveal melanoma
- Endometrial cancers with high microsatellite instability may benefit from immunotherapy
- Experts debate role of completion lymphadenectomy for node-positive melanoma
- ‘Explosion of genomic data’ should improve treatment of cutaneous T-cell lymphoma
- Extent of thyroid surgery often miscoded in cancer registries
- Gene mutations extend PFS, OS in ovarian cancer
- Hospital adherence to quality metrics may not improve colon cancer outcomes
-
- Insulin may increase mammographic density in women with diabetes
- Ipilimumab, interferon debated as standard adjuvant therapy for high-risk disease
- Mastectomy improves survival in younger, BRCA-positive women with ovarian cancer
- Multiple gene mutations may predict recurrence in malignant melanoma
- Oncogene expression may guide treatment, predict outcomes in head, neck cancer
- Patients with head and neck cancer often resort to cost-coping strategies
- Pembrolizumab shows early promise in repair-deficient endometrial cancer
- Physical activity does not impact mammographic density
-
- Sonidegib offers long-term disease control in basal cell carcinoma
- Updates in staging, management may benefit future of Merkel cell carcinoma treatment
- The potential of reversal agents for target-specific oral anticoagulants Amanda M. Morrill, PharmD, BCPS; Kristine C. Willett, PharmD, FASHP